Improving Access to Medications for Opioid Use Disorder in Medicare Beneficiaries
Official title: Access to Medications to Treat Opioid Use Disorder in the Medicare Population
Funded at Rand Corporation · NIH-11413739 · Data updated 2026-11-12
This project aims to make FDA-approved medications for opioid use disorder more accessible to people covered by Medicare.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rand Corporation NIH-funded |
| Lab location | 1 site (Santa Monica, United States) |
| Project start | September 15, 2025 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $2,174,516 |
| NIH project number | 4RF1AG088646-02 |
| Project ID | NIH-11413739 on NIH RePORTER |
Who could benefit from this research
✓Could help
Medicare beneficiaries diagnosed with opioid use disorder who may benefit from MOUD.
✕Less likely to help
Beneficiaries who do not have OUD or who do not need MOUD would not directly benefit.
What this research studies
If you have Medicare and struggle to access medications like methadone, buprenorphine, or naltrexone for opioid use disorder, this project looks at how coverage, location, and provider quality affect access. Researchers will use real-world data and policy analysis to identify barriers and test ways to improve MOUD availability for diverse groups, including rural residents and nonwhite beneficiaries. The goal is to inform policy and care practices so more patients can receive effective treatment.
Why it matters
Potential benefit: If successful, the project could lead to broader MOUD access for Medicare beneficiaries, reducing morbidity and mortality from opioid use disorder.
How similar studies have gone: Prior work has shown access barriers exist; this study seeks to deepen understanding and identify actionable improvements.
Where this research is happening
-
Rand Corporation
Santa Monica, United States Active
Researchers
- Principal investigator: Taylor, Erin a — Rand Corporation
- Study coordinator: Taylor, Erin a
Related research
Other NIH-funded projects on the same topics.
-
Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)
A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.
-
Precise epigenetic drugs for opioid addiction
A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.
-
Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans
This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.
-
Optimizing long-acting PrEP and opioid treatment for people in jails and prisons
This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.
-
Scaling up medications for opioid use disorder in residential treatment programs
This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.
-
Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN
This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.